Cervical cancer screening at crossroads

APMIS

Volumn 122, Issue 8, 2014, Pages 667-673

  Lynge, Elsebeth ^a   Rygaard, Carsten ^b   Baillet, Miguel Vazquez Prada ^a   Dugué, Pierre Antoine ^a   Sander, Bente Braad ^a   Bonde, Jesper ^b   Rebolj, Matejka ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Cancer; Cervix uteri; Cytology; Human papillomavirus; Screening

Indexed keywords

WART VIRUS VACCINE;

CANCER GRADING; CANCER INCIDENCE; CANCER SCREENING; CYTOLOGY; DENMARK; DISEASE CONTROL; HUMAN; PRIORITY JOURNAL; REVIEW; SEXUAL BEHAVIOR; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; WART VIRUS;

CANCER; CERVIX UTERI; CYTOLOGY; HUMAN PAPILLOMAVIRUS; SCREENING;

ADOLESCENT; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; DENMARK; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION; VAGINAL SMEARS; YOUNG ADULT;

EID: 84904565685     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/apm.12279     Document Type: Review

References (32)

1. Papanicolaou GN, Traut HF. The diagnostic value of vaginal smears in carcinoma of the uterus. Am J Obstet Gynecol 1941;42:193-206.
2. Wilson JMG, Jungner G. Principles and practice of screening for disease. Public Health Papers no 34. Geneva: WHO, 1968.
3. Dürst M, Gissmann L, Ikenberg H, zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA 1983;80:3812-5.
4. Helmerhorst TJ, Meijer CJ. Cervical cancer should be considered as a rare complication of oncogenic HPV infection rather than a STD. Int J Gynecol Cancer 2002;12:235-6.
5. Available at: http://www-dep.iarc.fr/NORDCAN/DK/frame.asp (Accessed 21 December 2013).
6. Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, et al., editors. Cancer Incidence in Five Continents, Vol. X (electronic version). Lyon: IARC. Available at: http://ci5.iarc.fr (Accessed 20 December 2013).
7. Preisler S, Rebolj M, Untermann A, Ejegod DM, Lynge E, Rygaard C, et al. Prevalence of human papillomavirus in 5, 072 consecutive cervical SurePath samples evaluated with the Roche cobas HPV real-time PCR assay. PLoS ONE 2013;8:e59765. doi: 10.1371/journal.pone.0059765.
8. Hakama M. Trends in the incidence of cervical cancer in the Nordic countries. In Magnus K, editor. Trends in Cancer Incidence. Washington: Hemisphere Publishing Corp., 1982: 270-92.
9. Sundhedsstyrelsen. Screening for Cervical Cancer - Recommendations. København: Sundhedsstyrelsen, 2012 [in Danish with English summary].
10. Barken SS, Rebolj M, Andersen ES, Lynge E. Frequency of cervical intraepithelial neoplasia treatment in a well-screened population. Int J Cancer 2012;130:2438-44.
11. Nøhr B, Jensen A, Frederiksen K, Tabor A, Kjær SK. Loop electrosurgical excision of the cervix and subsequent risk for spontaneous preterm delivery: a population-based study of singleton delivery during a 9-year period. Am J Obstet Gynecol 2009;201:33.e1-6. doi: 10.1016/j.ajog.2009.02.004.
12. Dansk Kvalitetsdatabase for Livmoderhaskræftscreening. Årsrapport 2012. Aarhus: Dansk Kvalitetsdatabase for Livmoderhaskræftscreening, 2012 [in Danish].
13. Kristensson JH, Sander BB, von Euler-Chelpin M, Lynge E. Predictors of non-participation in cervical screening in Denmark. Cancer Epidemiol 2014;38:174-80.
14. Dugué PA, Lynge E, Bjerregaard B, Rebolj M. Non-participation in screening: the case of cervical cancer in Denmark. Prev Med 2012;54:266-9.
15. Barken SS, Rebolj M, Lynge E, Junge J, Rygaard C. Outcomes in cervical screening using various cytology technologies: what's age got to do with it? Eur J Cancer Prev 2013;22:367-73.
16. Rask J, Lynge E, Franzmann M, Hansen B, Hjortebjerg A, Rygaard C, et al. Impact of technology an cytology outcome in cervical cancer screening of young and older women. Int J Cancer 2014;134:168-79.
17. Ronco G, Dillner J, Elfström KM, Tunesi S, Snijsers PJ, Arbyn M, et al., the International HPV screening working group. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of tour European randomized controlled trials. Lancet 2014;383:524-32.
18. Rebolj M, Preisler S, Ejegod DM, Bonde J, Rygaard C, Lynge E. Prevalence of human papillomavirus infection in unselected SurePath samples using the APTIMA HPV mRNA assay. J Mol Diagn 2013;15:670-7.
19. Rebolj M, Preisler S, Ejegod DM, Rygaard C, Lynge E, Bonde J. Disagreement between human papillomavirus assays in primary cervical screening: a challenge demonstrated in a population based split sample study. PlosOne 2014;9:e86835.
20. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000703/WC500021142.pdf (Accessed 27 January 2014).
21. Sander BB, Rebolj M, Valentiner-Branth P, Lynge E. Introduction of human papillomavirus in Nordic countries. Vaccine 2012;30:1425-33.
22. Available at: http://www.ssi.dk/English/News/EPI-NEWS/2012/No%2028-33%20-%202012.aspx (Accessed 12 December 2013).
23. Available at: http://www.ssi.dk/English/News/EPI-NEWS/2013/No%2020%20-%202013.aspx (Accessed 12 December 2013).
24. Available at: http://www.ssi.dk/Aktuelt/Nyheder/2014/2014%201%20epinyt%201-2%20HPV.aspx (Accessed 16 January 2014).
25. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al.; Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43.
26. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
27. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, et al.; HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009;374:301-14. Erratum in: Lancet 2010;376:1054.
28. Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med 2013;11:227 [Epub ahead of print].
29. Arnheim-Dahlström L, Pasternak B, Svanström H, Sparén P, Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ 2013;347:f5906. doi: 10.1136/bmj.f5906.
30. Kjær SK, Munk C, Junge J, Iftner T. Carcinogenic HPV prevalence and age-specific type distribution in 40, 382 women with normal cervical cytology, ASCUS/LSIL, HSIL, or cervical cancer: what is the potential for prevention? Cancer Causes Control 2014;25:179-89.
31. Kang WD, Choi HS, Kim SM. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)? Gynecol Oncol 2013;130:264-8.
32. Broberg G, Gyrd-Hansen D, Jonasson JM, Ryd M-L, Holtenman M, Milsom I, et al. Increasing participation in cervical cancer screening: offering a HPV self-test to long-term non-attendees as part of RACOMIP, a Swedish randomized controlled trial. Int J Cancer 2013;133:164-71.